3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Multiple Myeloma
55
Recurrence
7
Lymphoma
6
Neoplasms, Plasma Cell
5
Immunoglobulin Light-chain Amyloidosis
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Paraproteinemias
2
Neoplasms
2
Lymphoma, T-Cell
2
Lymphoma, Mantle-Cell
2
Leukemia, Myeloid, Acute
2
beta-Thalassemia
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thalassemia
1
Sarcoma, Myeloid
1
Prostatic Neoplasms
1
Plasmablastic Lymphoma
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Multi-centric Castleman's Disease
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lymphadenopathy
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Carboplatin
3
durvalumab
2
Tretinoin
2
Paclitaxel
2
Irinotecan
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tegafur-gimeracil-oteracil
1
talazoparib
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Surgical Procedures, Operative
1
Standard of Care
1
STA 9090
1
SGN-LIV1A
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Bortezomib
×
90 days
×
Clear all
No trials found.